With over 30 years of experience in medicine and 15 years in drug development, I bring a wealth of expertise to my role as Clinical Strategist at EvoDenovo. Prior to joining EvoDenovo, I led the clinical development of T121 at Thar Pharmaceutics, which was acquired by Grünenthal GmbH. As Medical Director at Redhill Therapeutics, I also oversaw the clinical development and FDA approval of Talicia®, which is now commercially available. Additionally, I served as VP of Medical Affairs at Lev Pharmaceuticals, where I spearheaded the clinical development of Cinryze®, an FDA-approved drug that played a key role in Lev’s acquisition by ViroPharma for $618 million.

My past positions have included roles as Medical Director at Aetna/US Healthcare, Internist at Hillside Medical Associates, and President of the Staff Society and Chairman of Performance Improvement at Long Island Jewish Medical Center. I completed my residency in Internal Medicine at Long Island Jewish Medical Center and hold an MD from Albert Einstein College of Medicine and a BA in Biology from Columbia University.

With my extensive preclinical and clinical background, I am poised to drive the success of EvoDenovo’s drug development programs, bringing to the table a deep well of experience and a passionate dedication to the field.